Actinium Signs Cooperative Research and Development Agreement with NCI to Further Enhance Clinical & Non-clinical Development of Actimab-A for the Treatment of AML and Other Hematologic Malignancies February 22, 2023
Ph 3 Study of Uproleselan in R/R AML to continue to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee February 22, 2023
Final Topline Data from Successful European Ph 1 monotherapy Trial of Annamycin in R/R AML patients announced February 22, 2023
Tecartus® CAR T-Cell Therapy Demonstrates OS Benefit In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial In R/R B-Cell Acute Lymphoblastic Leukemia February 22, 2023
2023 EBMT-EHA: Encouraging initial safety and efficacy data for point-of-care manufactured GLPG5201 CAR-T in rrCLL presented February 22, 2023
Successful Dosing of Final Patient in ACHIEVE Safety Cohort of TCB008 Trial Announced February 8, 2023
TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of CRR in R/R CLL Patients February 1, 2023
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology January 17, 2023
Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology January 4, 2023
Calquence approved in Japan for adults with treatment-naïve chronic lymphocytic leukaemia January 4, 2023
80% ORR reported in Final Cohort of Ph 1 Single Agent Trial of Annamycin for the Treatment of AML December 19, 2022
Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned December 13, 2022
U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Patients with R/R KMT2A- Rearranged (MLLr) Acute Leukemia December 12, 2022
FDA Approves REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with R/R AML with a Susceptible IDH1 Mutation December 5, 2022
